401 related articles for article (PubMed ID: 33762322)
21. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
DeMaria PJ; Bilusic M; Park DM; Heery CR; Donahue RN; Madan RA; Bagheri MH; Strauss J; Shen V; Marté JL; Steinberg SM; Schlom J; Gilbert MR; Gulley JL
Oncologist; 2021 May; 26(5):e847-e858. PubMed ID: 33594772
[TBL] [Abstract][Full Text] [Related]
22. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
Sonpavde G; Wang M; Peterson LE; Wang HY; Joe T; Mims MP; Kadmon D; Ittmann MM; Wheeler TM; Gee AP; Wang RF; Hayes TG
Invest New Drugs; 2014 Apr; 32(2):235-242. PubMed ID: 23609828
[TBL] [Abstract][Full Text] [Related]
23. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
24. Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.
Hamilton DH; Roselli M; Ferroni P; Costarelli L; Cavaliere F; Taffuri M; Palena C; Guadagni F
Endocr Relat Cancer; 2016 Oct; 23(10):783-796. PubMed ID: 27580659
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
26. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM; Donahue RN; Tsai YT; Manu M; Palena C; Gatti-Mays ME; Marté JL; Madan RA; Karzai F; Heery CR; Strauss J; Abdul-Sater H; Cordes L; Schlom J; Gulley JL; Bilusic M
Oncologist; 2020 Jul; 25(7):560-e1006. PubMed ID: 31876334
[TBL] [Abstract][Full Text] [Related]
27. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
28. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Heery CR; Madan RA; Stein MN; Stadler WM; Di Paola RS; Rauckhorst M; Steinberg SM; Marté JL; Chen CC; Grenga I; Donahue RN; Jochems C; Dahut WL; Schlom J; Gulley JL
Oncotarget; 2016 Oct; 7(42):69014-69023. PubMed ID: 27486817
[TBL] [Abstract][Full Text] [Related]
29. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
[TBL] [Abstract][Full Text] [Related]
31. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
[TBL] [Abstract][Full Text] [Related]
32. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
33. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
34. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Gulley JL; Arlen PM; Madan RA; Tsang KY; Pazdur MP; Skarupa L; Jones JL; Poole DJ; Higgins JP; Hodge JW; Cereda V; Vergati M; Steinberg SM; Halabi S; Jones E; Chen C; Parnes H; Wright JJ; Dahut WL; Schlom J
Cancer Immunol Immunother; 2010 May; 59(5):663-74. PubMed ID: 19890632
[TBL] [Abstract][Full Text] [Related]
35. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
36. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Br J Cancer; 2004 Aug; 91(4):688-94. PubMed ID: 15280930
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Pantuck AJ; van Ophoven A; Gitlitz BJ; Tso CL; Acres B; Squiban P; Ross ME; Belldegrun AS; Figlin RA
J Immunother; 2004; 27(3):240-53. PubMed ID: 15076142
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
Kongsted P; Borch TH; Ellebaek E; Iversen TZ; Andersen R; Met Ö; Hansen M; Lindberg H; Sengeløv L; Svane IM
Cytotherapy; 2017 Apr; 19(4):500-513. PubMed ID: 28215654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]